KEY FINDINGS Alopecia is the condition of hair loss, hair thinning, or balding anywhere in the body that can be an outcome of various malignancies.Cases of hormonal imbalance and aging can enhance the chances of developing chronic diseases like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people.
The global alopecia treatment market is expected to proliferate at 5.51% CAGR during the forecasting years of 2019-2027.
MARKET INSIGHTS Growing disposable income coupled with the rising penetration of celebrity culture among the mass and the increased emphasis on visual appearance is contributing to the alopecia treatment market growth.Increasing cases of chronic diseases such as Polycystic Ovary Syndrome (PCOS), Rheumatoid Arthritis and cancer causes a higher rate of occurrence of alopecia which is further profiting the said market.
The high economic development in the developing countries and the initiatives of organizations, such as National Alopecia Areata Foundation, American Hair Loss Association, etc. across several corners of the world are helping to spread awareness about alopecia and the available treatments are resulting in growth in healthcare expenditure specifically for the market.
REGIONAL INSIGHTS The global market for alopecia treatment is geographically bifurcated into several regions, i.e., North America, Europe, Asia Pacific, and the remaining countries constituting the Rest of World segment. The alopecia (hair loss) treatment market in North America is expected to hold the largest share by 2027 and is expected to grow at a CAGR of xx% during the forecasting years. The cumulative form of investment in research and development (R&D) coupled with the better & efficient healthcare facilities are contributing to the largest shareholding capacity of this region over the market.
COMPETITIVE INSIGHTS Concert Pharmaceuticals Inc., Histogen Inc., Dr Reddy’s Laboratories Ltd., Merck & Co., Inc., Alès Groupe, Alpecin, Sun Pharmaceutical Industries Ltd., Vitabiotics Ltd., Aclaris Therapeutics Inc., Johnson and Johnson, GlaxoSmithKline, Daiichi Sankyo, Inc., Lifes2good, Cipla and HCell Inc. are some of the companies operating in the global market.
Companies mentioned 1. ACLARIS THERAPEUTICS INC. 2. ALÈS GROUPE 3. ALPECIN 4. CIPLA 5. CONCERT PHARMACEUTICALS INC. 6. DAIICHI SANKYO, INC. 7. DR REDDY’S LABORATORIES LTD. 8. GLAXOSMITHKLINE 9. HCELL INC. 10. HISTOGEN INC. 11. JOHNSON AND JOHNSON 12. LIFES2GOOD 13. MERCK & CO., INC. 14. SUN PHARMACEUTICAL INDUSTRIES LTD. 15. VITABIOTICS LTD.
Our reports have been used by over 10K customers, including:
170 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Cartilage Repair/ Cartilage Regeneration Market to Reach $1.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Cartilage Repair/ Cartilage Regeneration estimated at US$592.3 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at aCAGR...
257 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Narcolepsy Therapeutics Market to Reach $3.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Narcolepsy Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 11.3% over the analysis period...
276 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Vaginitis Therapeutics Market to Reach $4.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Vaginitis Therapeutics estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$4.4 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027....
181 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Brain Tumor Therapeutics Market to Reach $3.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Brain Tumor Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.3 Billion by 2027, growing at aCAGR of 9.6% over the period 2020-2027....
125 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Non-Hodgkin Lymphoma Therapeutics Market to Reach $8.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Non-Hodgkin Lymphoma Therapeutics estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$8.1 Billion by 2027, growing at a CAGR of 6% over...
189 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Plasma Protein Therapeutics Market to Reach $32.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Plasma Protein Therapeutics estimated at US$24 Billion in the year 2020, is projected to reach a revised size of US$32.8 Billion by 2027, growing at a CAGR of 4.6% over the analysis...
Global Oncolytic Virus Therapies Market to Reach $962.0 Million by 2030 Market Report Coverage - Oncolytic Virus Therapies Market Segmentation • Commercialized Therapies: Imlygic, Oncorine, and RIGVIR • Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV • Type of Virus: Genetically...
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Drugs in Development, 2021, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline...
Amyloidosis (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Drugs in Development, 2021, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid...
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drugs in Development, 2021 Summary According to the recently published report ’Lysosomal Alpha Glucosidase - Drugs in Development, 2021’; Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or...
Neurological Disorder
Therapy
World
Belgium
Number Of R&D Personnel
Pharmaceutical Exports
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.